[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 1,572
Citations 0
Clinical Trials Update
March 24/31, 2020

“Superdonor” Fecal Microbiota Transplant Effective for IBS

JAMA. 2020;323(12):1124. doi:10.1001/jama.2020.2812

Fecal microbiota transplant (FMT) using a single “superdonor” produced high rates of clinical response in patients with irritable bowel syndrome (IBS) in a trial published in Gut. Two previous randomized clinical trials of FMT for IBS had conflicting results.

The study randomized 165 patients to receive either a placebo (30 g of their own feces) or 30 g or 60 g of FMT. The transplant material, obtained from a 36-year-old healthy white man, was stored frozen and administered via gastroscope.

Treatment response, defined as a decrease of 50 or more points on an IBS symptom score, increased with dose, occurring in 23.6% of the placebo group, 76.9% of the 30-g FMT group, and 89.1% of the 60-g FMT group. Fatigue and quality of life also improved in the treatment groups compared with the placebo group, and adverse events were mild.

Choosing a donor with “a favourable specific microbial signature is essential for successful FMT,” the authors wrote.